Ask Your Lawmakers to CoSponsor the Patients Access to Treatment Act HR 4209

Biologic drugs are not appropriate for every arthritis patient, but many have been helped by them. It's a sad situation when a patient can't be treated with biologics because, in their case, the drugs are unaffordable. Some health insurance companies place biologic drugs into "specialty tiers" that leave patients with high co-insurance or cost-sharing. Specialty tiers can require that patients pay 25% to 33% of drug cost which can amount to hundreds or even thousands of dollars each month, depending on the drug.

According to the American College of Rheumatology (ACR), Representatives David McKinley (R-WV) and Lois Capps (D-CA) have introduced the Patients' Access to Treatment Act (H.R. 4209). The legislation would place specialty drugs within the same classification as Tier III non-preferred drugs. The biologic drugs would then become affordable for more patients. Want to help? Go here to contact your lawmakers today and ask them to co-sponsor H.R. 4209.

Related Information:

• More About Biologic Drugs

Ask Your Lawmakers to CoSponsor the Patients Access to Treatment Act HR 4209

Biologic drugs are not appropriate for every arthritis patient, but many have been helped by them. It's a sad situation when a patient can't be treated with biologics because, in their case, the drugs are unaffordable. Some health insurance companies place biologic drugs into "specialty tiers" that leave patients with high co-insurance or cost-sharing. Specialty tiers can require that patients pay 25% to 33% of drug cost which can amount to hundreds or even thousands of dollars each month, depending on the drug.

According to the American College of Rheumatology (ACR), Representatives David McKinley (R-WV) and Lois Capps (D-CA) have introduced the Patients' Access to Treatment Act (H.R. 4209). The legislation would place specialty drugs within the same classification as Tier III non-preferred drugs. The biologic drugs would then become affordable for more patients. Want to help? Go here to contact your lawmakers today and ask them to co-sponsor H.R. 4209.

Related Information:

• More About Biologic Drugs

Ask Your Lawmakers to CoSponsor the Patients Access to Treatment Act HR 4209

Biologic drugs are not appropriate for every arthritis patient, but many have been helped by them. It's a sad situation when a patient can't be treated with biologics because, in their case, the drugs are unaffordable. Some health insurance companies place biologic drugs into "specialty tiers" that leave patients with high co-insurance or cost-sharing. Specialty tiers can require that patients pay 25% to 33% of drug cost which can amount to hundreds or even thousands of dollars each month, depending on the drug.

According to the American College of Rheumatology (ACR), Representatives David McKinley (R-WV) and Lois Capps (D-CA) have introduced the Patients' Access to Treatment Act (H.R. 4209). The legislation would place specialty drugs within the same classification as Tier III non-preferred drugs. The biologic drugs would then become affordable for more patients. Want to help? Go here to contact your lawmakers today and ask them to co-sponsor H.R. 4209.

Related Information:

• More About Biologic Drugs

Ask Your Lawmakers to CoSponsor the Patients Access to Treatment Act HR 4209

Biologic drugs are not appropriate for every arthritis patient, but many have been helped by them. It's a sad situation when a patient can't be treated with biologics because, in their case, the drugs are unaffordable. Some health insurance companies place biologic drugs into "specialty tiers" that leave patients with high co-insurance or cost-sharing. Specialty tiers can require that patients pay 25% to 33% of drug cost which can amount to hundreds or even thousands of dollars each month, depending on the drug.

According to the American College of Rheumatology (ACR), Representatives David McKinley (R-WV) and Lois Capps (D-CA) have introduced the Patients' Access to Treatment Act (H.R. 4209). The legislation would place specialty drugs within the same classification as Tier III non-preferred drugs. The biologic drugs would then become affordable for more patients. Want to help? Go here to contact your lawmakers today and ask them to co-sponsor H.R. 4209.

Related Information:

• More About Biologic Drugs

Ask Your Lawmakers to CoSponsor the Patients Access to Treatment Act HR 4209

Biologic drugs are not appropriate for every arthritis patient, but many have been helped by them. It's a sad situation when a patient can't be treated with biologics because, in their case, the drugs are unaffordable. Some health insurance companies place biologic drugs into "specialty tiers" that leave patients with high co-insurance or cost-sharing. Specialty tiers can require that patients pay 25% to 33% of drug cost which can amount to hundreds or even thousands of dollars each month, depending on the drug.

According to the American College of Rheumatology (ACR), Representatives David McKinley (R-WV) and Lois Capps (D-CA) have introduced the Patients' Access to Treatment Act (H.R. 4209). The legislation would place specialty drugs within the same classification as Tier III non-preferred drugs. The biologic drugs would then become affordable for more patients. Want to help? Go here to contact your lawmakers today and ask them to co-sponsor H.R. 4209.

Related Information:

• More About Biologic Drugs

Ask Your Lawmakers to CoSponsor the Patients Access to Treatment Act HR 4209

Biologic drugs are not appropriate for every arthritis patient, but many have been helped by them. It's a sad situation when a patient can't be treated with biologics because, in their case, the drugs are unaffordable. Some health insurance companies place biologic drugs into "specialty tiers" that leave patients with high co-insurance or cost-sharing. Specialty tiers can require that patients pay 25% to 33% of drug cost which can amount to hundreds or even thousands of dollars each month, depending on the drug.

According to the American College of Rheumatology (ACR), Representatives David McKinley (R-WV) and Lois Capps (D-CA) have introduced the Patients' Access to Treatment Act (H.R. 4209). The legislation would place specialty drugs within the same classification as Tier III non-preferred drugs. The biologic drugs would then become affordable for more patients. Want to help? Go here to contact your lawmakers today and ask them to co-sponsor H.R. 4209.

Related Information:

• More About Biologic Drugs

Ask Your Lawmakers to CoSponsor the Patients Access to Treatment Act HR 4209

Biologic drugs are not appropriate for every arthritis patient, but many have been helped by them. It's a sad situation when a patient can't be treated with biologics because, in their case, the drugs are unaffordable. Some health insurance companies place biologic drugs into "specialty tiers" that leave patients with high co-insurance or cost-sharing. Specialty tiers can require that patients pay 25% to 33% of drug cost which can amount to hundreds or even thousands of dollars each month, depending on the drug.

According to the American College of Rheumatology (ACR), Representatives David McKinley (R-WV) and Lois Capps (D-CA) have introduced the Patients' Access to Treatment Act (H.R. 4209). The legislation would place specialty drugs within the same classification as Tier III non-preferred drugs. The biologic drugs would then become affordable for more patients. Want to help? Go here to contact your lawmakers today and ask them to co-sponsor H.R. 4209.

Related Information:

• More About Biologic Drugs